계산
순이익률(Net Profit Margin Ratio) | = | 100 | × | 주주에게 귀속되는 순이익(손실)1 | ÷ | 순 매출1 | |
---|---|---|---|---|---|---|---|
2019. 12. 31. | -32.76% | = | 100 | × | (5,271,000) | ÷ | 16,088,900) |
2018. 12. 31. | -32.28% | = | 100 | × | (5,096,400) | ÷ | 15,787,400) |
2017. 12. 31. | -25.88% | = | 100 | × | (4,125,500) | ÷ | 15,940,700) |
2016. 12. 31. | 102.76% | = | 100 | × | 14,973,400) | ÷ | 14,570,600) |
2015. 12. 31. | 25.98% | = | 100 | × | 3,915,200) | ÷ | 15,071,000) |
2014. 12. 31. | -12.48% | = | 100 | × | (1,630,500) | ÷ | 13,062,300) |
2013. 12. 31. | -8.65% | = | 100 | × | (750,400) | ÷ | 8,677,600) |
2012. 12. 31. | 1.64% | = | 100 | × | 97,300) | ÷ | 5,914,900) |
2011. 12. 31. | 5.69% | = | 100 | × | 260,900) | ÷ | 4,584,400) |
2010. 12. 31. | 5.17% | = | 100 | × | 184,400) | ÷ | 3,566,900) |
2009. 12. 31. | 7.95% | = | 100 | × | 222,000) | ÷ | 2,793,000) |
2008. 12. 31. | 9.40% | = | 100 | × | 238,379) | ÷ | 2,535,501) |
2007. 12. 31. | 5.65% | = | 100 | × | 141,030) | ÷ | 2,496,651) |
2006. 12. 31. | -22.48% | = | 100 | × | (445,005) | ÷ | 1,979,244) |
2005. 12. 31. | 8.40% | = | 100 | × | 138,233) | ÷ | 1,646,203) |
보고서 기준: 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
1 US$ 단위 천
경쟁사와의 비교
Allergan PLC | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019. 12. 31. | -32.76% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | — | 31.45% | 26.91% | 14.47% |
2018. 12. 31. | -32.28% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | — | 20.79% | 36.42% | 12.06% |
2017. 12. 31. | -25.88% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | — | 40.55% | 20.41% | 10.64% |
2016. 12. 31. | 102.76% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | — | 13.66% | 18.42% | 11.06% |
2015. 12. 31. | 25.98% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | — | 14.25% | 15.50% | 11.64% |
2014. 12. 31. | -12.48% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | — | 18.42% | 12.34% | 11.22% |
2013. 12. 31. | -8.65% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | — | 42.65% | 20.16% | 9.73% |
2012. 12. 31. | 1.64% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | — | 24.70% | 54.43% | 9.42% |
2011. 12. 31. | 5.69% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | — | 14.84% | -49.74% | 11.34% |
2010. 12. 31. | 5.17% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | — | 12.18% | -22.76% | 9.60% |
2009. 12. 31. | 7.95% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | — | 17.27% | -17.88% | 8.41% |
2008. 12. 31. | 9.40% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | — | 16.78% | -34.69% | 9.47% |
2007. 12. 31. | 5.65% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | — | 16.82% | -84.46% | 7.81% |
2006. 12. 31. | -22.48% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | — | 39.98% | -161.30% | 4.46% |
2005. 12. 31. | 8.40% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | — | 15.76% | -144.19% | 8.48% |
보고서 기준: 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
산업 부문과의 비교: 제약, 생명공학 및 생명과학
Allergan PLC | 제약, 생명공학 및 생명과학 | |
---|---|---|
2019. 12. 31. | -32.76% | 23.02% |
2018. 12. 31. | -32.28% | 19.29% |
2017. 12. 31. | -25.88% | 13.08% |
2016. 12. 31. | 102.76% | 20.92% |
2015. 12. 31. | 25.98% | 21.42% |
2014. 12. 31. | -12.48% | 21.52% |
2013. 12. 31. | -8.65% | 22.24% |
2012. 12. 31. | 1.64% | 18.66% |
2011. 12. 31. | 5.69% | 15.76% |
2010. 12. 31. | 5.17% | 15.46% |
2009. 12. 31. | 7.95% | 26.03% |
2008. 12. 31. | 9.40% | 18.39% |
2007. 12. 31. | 5.65% | 16.10% |
2006. 12. 31. | -22.48% | 22.37% |
2005. 12. 31. | 8.40% | 18.45% |
보고서 기준: 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
업계와의 비교: 의료
Allergan PLC | 의료 | |
---|---|---|
2019. 12. 31. | -32.76% | 10.09% |
2018. 12. 31. | -32.28% | 9.13% |
2017. 12. 31. | -25.88% | 7.75% |
2016. 12. 31. | 102.76% | 9.91% |
2015. 12. 31. | 25.98% | 10.98% |
2014. 12. 31. | -12.48% | 11.39% |
2013. 12. 31. | -8.65% | 11.99% |
2012. 12. 31. | 1.64% | 11.19% |
2011. 12. 31. | 5.69% | 10.02% |
2010. 12. 31. | 5.17% | 10.09% |
2009. 12. 31. | 7.95% | 14.33% |
2008. 12. 31. | 9.40% | 10.62% |
2007. 12. 31. | 5.65% | 10.58% |
2006. 12. 31. | -22.48% | 13.20% |
2005. 12. 31. | 8.40% | 12.89% |
보고서 기준: 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).